Dr. Zahi Mitri
Claim this profileOHSU Knight Cancer Institute
Expert in Breast Cancer
Studies Cancer
15 reported clinical trials
37 drugs studied
Area of expertise
1Breast Cancer
Global LeaderHER2 positive
ER positive
Stage IV
2Cancer
HER2 positive
ER positive
PR positive
Affiliated Hospitals
Clinical Trials Zahi Mitri is currently running
Combination Therapy
for Triple Negative Breast Cancer
This phase II study assesses the efficacy of the combination of olaparib with durvalumab, selumetinib, or capivasertib or ceralasertib alone in the treatment of patients with metastatic triple negative breast cancer (TNBC). Olaparib may stop growth of tumor cells by inhibiting some of the enzymes (ADP ribose polymerase \[PARP\]) needed for cell growth. Durvalumab, a monoclonal antibody, inhibits the growth and spread of tumors by stimulating the patient's antitumor immune response. Selumetinib, capivasertib, and ceralasertib are inhibitor drugs that may stop the growth of tumor cells by blocking some of the enzymes (MEK, AKT, ATR) needed for cell growth. Giving olaparib together with durvalumab, selumetinib, or capivasertib or giving ceralasertib alone may provide an effective method to treat patients with metastatic triple negative breast cancer.
Recruiting1 award Phase 215 criteria
DNA-Guided Adjuvant Therapy
for Breast Cancer
A randomized, Phase II trial of circulating tumor DNA-guided second line Adjuvant therapy for high Residual risk, stage II-III, Estrogen Receptor positive, HER-2 negative breast cancer (DARE)
Recruiting1 award Phase 29 criteria
More about Zahi Mitri
Clinical Trial Related1 year of experience running clinical trials · Led 15 trials as a Principal Investigator · 5 Active Clinical TrialsTreatments Zahi Mitri has experience with
- Abemaciclib
- Trastuzumab
- Fulvestrant
- Tucatinib
- Placebo
- Ladiratuzumab Vedotin
Breakdown of trials Zahi Mitri has run
Breast Cancer
Cancer
Tumors
Ovarian Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Zahi Mitri specialize in?
Zahi Mitri focuses on Breast Cancer and Cancer. In particular, much of their work with Breast Cancer has involved HER2 positive patients, or patients who are ER positive.
Is Zahi Mitri currently recruiting for clinical trials?
Yes, Zahi Mitri is currently recruiting for 5 clinical trials in Portland Oregon. If you're interested in participating, you should apply.
Are there any treatments that Zahi Mitri has studied deeply?
Yes, Zahi Mitri has studied treatments such as Abemaciclib, Trastuzumab, Fulvestrant.
What is the best way to schedule an appointment with Zahi Mitri?
Apply for one of the trials that Zahi Mitri is conducting.
What is the office address of Zahi Mitri?
The office of Zahi Mitri is located at: OHSU Knight Cancer Institute, Portland, Oregon 97239 United States. This is the address for their practice at the OHSU Knight Cancer Institute.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.